Download PDF
Dialyse aktuell 2007; 11(2): 52-54
DOI: 10.1055/s-2007-983932
Markt und Forschung

© Georg Thieme Verlag Stuttgart · New York

Ergebnisse der RIND-Studie erbringen den Nachweis - Klarer Überlebensvorteil für Dialysepatienten bei kalziumfreier Phosphatbindertherapie

Further Information

Publication History

Publication Date:
06 June 2007 (online)

Also available at
  Permissions and Reprints
Preview

Wie die kürzlich im Journal „Kidney International” publizierten Ergebnisse der RIND[1]-Studie [2] zeigen, weisen Patienten, die mit Sevelamer (Renagel®) therapiert werden, eine signifikant geringere Mortalität auf als Patienten, denen kalziumhaltige Phosphatbinder verabreicht werden. Damit liefern die Daten den Nachweis für eine direkte Korrelation zwischen Kalzifizierung, Mortalität und Phosphatbindertherapie.

Literatur

  • 1 Asmus HG, Braun J, Krause R. et al. . Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density.  Nephrol Dial Transplant. 2005;  20 1653-1661
    Search in Google Scholar
  • 2 Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM.. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease.  Hypertension. 2001;  38
    Search in Google Scholar
  • 3 Block GA. et al. .Effect of coronary calcification and phosphate binder. Kidney(Online-Version: ) 2007
    Search in Google Scholar
  • 4 Block GA, Klassen PS, Lazarus JM. et al. . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.  J Am Soc Nephrol. 2004;  15 2208-2218
    Search in Google Scholar
  • 5 Block GA, Spiegel DM, Ehrlich J. et al. . Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.  Kidney Int. 2005;  68 1815-1824
    Search in Google Scholar
  • 6 Braun J, Asmus HG, Holzer H. et al. . Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification.  Clin Nephrol. 2004;  62 104-115
    Search in Google Scholar
  • 7 Chertow GM, Burke SK, Raggi P.. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.  Kidney Int. 2002;  62 245-252
    Search in Google Scholar
  • 8 Foley RN, Parfrey PS, Sarnak MJ.. Clinical epidemiology of cardiovascular disease in chronic renal disease.  Am J Kidney Dis. 1998;  32 112-119
    Search in Google Scholar
  • 9 Goodman WG, Goldin J, Kuizon BD. et al. . Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis.  N Engl J Med. 2000;  342 1478-1483
    Search in Google Scholar
  • 10 Groß. et al. .ASN 2005/Abstract
  • 11 Guérin AP, London GM, Marchais SJ, Metivier F.. Arterial stiffening and vascular calcification in end-stage renal disease.  Nephrol Dial Transplant. 2000;  15 1014-1021
    Search in Google Scholar
  • 12 London GM, Guérin AP, Marchais SJ. et al. . Arterial media calcification in end-stage renal disease: Impact on all cause and cardiovascular mortality.  Nephrol Dial Transplant. 2003;  18 1731-1740
    Search in Google Scholar
  • 13 Young EW, Akiba T, Albert JM. et al. . Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).  Am J Kidney Dis. 2004;  44 34-38
    Search in Google Scholar
  • 14 Young EW, Albert JM, Satayathum S. et al. . Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study.  Kidney Int. 2005;  67 1179-1187
    Search in Google Scholar

1 Renagel in New Dialysis